https://news.medxy.ai/ja/soul%e8%a9%a6%e9%a8%93%e3%81%a7%e3%81%bf%e3%81%9f%e7%b5%8c%e5%8f%a3%e3%82%bb%e3%83%9e%e3%82%b0%e3%83%ab%e3%83%81%e3%83%89%e3%81%ae%e5%bf%83%e8%a1%80%e7%ae%a1%e3%83%99%e3%83%8d%e3%83%95%e3%82%a3/Medxy AIja2026-07-22T14:28:16-07:00SOUL試験でみた経口セマグルチドの心血管ベネフィット：ベースラインHbA1c・BMIとその変化が臨床転帰に及ぼす影響 https://news.medxy.ai/vi/semaglutide-duong-uong-va-loi-ich-tim-mach-trong-thu-nghiem-soul-anh-huong-cua-hba1c-va-bmi-nen-cung-nhu-su-thay-doi-cua-chung-den-ket-cuc-lam-sang/Medxy AIvi2026-07-22T14:27:57-07:00Semaglutide đường uống và lợi ích tim mạch trong thử nghiệm SOUL: Ảnh hưởng của HbA1c và BMI nền cũng như sự thay đổi của chúng đến kết cục lâm sàng https://news.medxy.ai/oral-semaglutide-and-cardiovascular-benefits-in-the-soul-trial-impact-of-baseline-and-changes-in-hba1c-and-bmi-on-clinical-outcomes/Medxy AIen2026-07-22T14:27:06-07:00Oral Semaglutide and Cardiovascular Benefits in the SOUL Trial: Impact of Baseline and Changes in HbA1c and BMI on Clinical Outcomes https://news.medxy.ai/zh/bmi-normalization-reduces-risk-of-t1dm-2/Medxy AIzh2026-07-22T11:52:47-07:00BMI正常化显著降低青少年1型糖尿病进展风险 https://news.medxy.ai/ja/bmi-normalization-reduces-risk-of-t1dm/Medxy AIja2026-07-22T11:52:03-07:00若年の1型糖尿病進行、BMI正常化で大幅に抑制 https://news.medxy.ai/vi/bmi-normalization-significantly-reduces-risk-of-t1dm/Medxy AIvi2026-07-22T11:51:42-07:00Bình thường hóa BMI giúp giảm đáng kể nguy cơ tiến triển đái tháo đường type 1 ở người trẻ https://news.medxy.ai/bmi-normalization-significantly-reduces-risk-of-type-1-diabetes-progression-in-youth/Medxy AIen2026-07-22T11:50:50-07:00BMI Normalization Significantly Reduces Risk of Type 1 Diabetes Progression in Youth https://news.medxy.ai/ja/glp-1-receptor-agonists-a-breakthrough-in-reducing-atherosclerosis-and-cardiovascular-risk/Medxy AIja2026-07-22T08:44:37-07:00GLP-1受容体作動薬：糖尿病や肥満を超えて、動脈硬化と心血管リスクを低減する新たな展開 https://news.medxy.ai/glp-1-receptor-agonists-a-breakthrough-in-reducing-atherosclerosis-and-cardiovascular-risk-beyond-diabetes-and-obesity/Medxy AIen2026-07-22T08:42:08-07:00GLP-1 Receptor Agonists: A Breakthrough in Reducing Atherosclerosis and Cardiovascular Risk Beyond Diabetes and Obesity https://news.medxy.ai/zh/exposure-to-pm2-5-constituents-and-chd-risk/Medxy AIzh2026-07-21T15:22:15-07:00长期暴露于PM2.5与冠心病风险的关系 https://news.medxy.ai/ja/exposure-to-pm2-5-constituents-and-coronary-heart-disease-risk/Medxy AIja2026-07-21T15:21:45-07:00中国におけるPM2.5成分の長期曝露と冠動脈疾患リスク：包括的レビュー https://news.medxy.ai/vi/long-term-exposure-to-pm2-5-constituents-and-coronary-heart-disease-risk/Medxy AIvi2026-07-21T15:21:09-07:00Phơi nhiễm dài hạn với các thành phần PM2.5 và nguy cơ bệnh mạch vành ở Trung Quốc: Tổng quan toàn diện https://news.medxy.ai/long-term-exposure-to-pm2-5-constituents-and-coronary-heart-disease-risk-in-china-a-comprehensive-review/Medxy AIen2026-07-21T15:19:42-07:00Long-Term Exposure to PM2.5 Constituents and Coronary Heart Disease Risk in China: A Comprehensive Review https://news.medxy.ai/zh/medically-tailored-groceries-on-glycemic-control-in-adults-with-t2dm/Medxy AIzh2026-07-21T15:14:22-07:00医嘱定制食品杂货对 Medicaid 承保2型糖尿病成人血糖控制的影响：随机对照试验带来的启示 https://news.medxy.ai/ja/medically-tailored-groceries-on-glycemic-control-in-adults-with-type-2-diabetes/Medxy AIja2026-07-21T15:13:52-07:00Medicaid加入の2型糖尿病成人における血糖管理への医療的に調整された食料品の影響：ランダム化比較試験からの知見 https://news.medxy.ai/vi/medically-tailored-groceries-on-glycemic-control-in-medicaid-insured-adults-with-type-2-diabetes/Medxy AIvi2026-07-21T15:13:17-07:00Tác động của các gói thực phẩm được thiết kế theo nhu cầu y tế đối với việc kiểm soát đường huyết ở người trưởng thành mắc đái tháo đường tuýp 2 có bảo hiểm Medicaid https://news.medxy.ai/impact-of-medically-tailored-groceries-on-glycemic-control-in-medicaid-insured-adults-with-type-2-diabetes-insights-from-a-randomized-controlled-trial/Medxy AIen2026-07-21T15:12:05-07:00Impact of Medically Tailored Groceries on Glycemic Control in Medicaid-Insured Adults with Type 2 Diabetes: Insights from a Randomized Controlled Trial https://news.medxy.ai/zh/digital-standardized-skin-care-enhances-outcomes-in-patients-with-acne-rosacea-comorbidity/Medxy AIzh2026-07-21T14:56:11-07:00数字化标准化皮肤护理方案可改善痤疮合并玫瑰痤疮患者结局：一项真实世界纵向队列研究 https://news.medxy.ai/ja/digital-standardized-skin-care-regimen-enhances-outcomes-in-patients-with-acne-rosacea/Medxy AIja2026-07-21T14:55:52-07:00ニキビ・酒さ併存に対するデジタル標準化スキンケアが奏効：リアルワールド縦断コホートからの知見 https://news.medxy.ai/vi/digital-standardized-skin-care-regimen-enhances-outcomes-in-patients-with-acne-rosacea-comorbidity/Medxy AIvi2026-07-21T14:55:28-07:00Phác đồ chăm sóc da chuẩn hóa kỹ thuật số cải thiện kết cục ở bệnh nhân đồng mắc mụn trứng cá – rosacea: bằng chứng từ một đoàn hệ theo dõi dọc trong thực tế https://news.medxy.ai/digital-standardized-skin-care-regimen-enhances-outcomes-in-patients-with-acne-rosacea-comorbidity-insights-from-a-real-world-longitudinal-cohort/Medxy AIen2026-07-21T14:54:42-07:00Digital Standardized Skin Care Regimen Enhances Outcomes in Patients with Acne-Rosacea Comorbidity: Insights from a Real-World Longitudinal Cohort https://news.medxy.ai/zh/carotid-artery-depth-for-safe-hemostatic-net-use-in-surgery/Medxy AIzh2026-07-21T14:49:10-07:00颈动脉有多深？面部拉皮术中安全使用止血网的解剖学依据 https://news.medxy.ai/ja/carotid-artery-depth-for-safe-hemostatic-net-use-in-facelift-surgery/Medxy AIja2026-07-21T14:48:53-07:00その下に潜むもの：フェイスリフト手術で止血ネットを安全に用いるための頸動脈深度の読み解き https://news.medxy.ai/vi/navigating-carotid-artery-depth-for-safe-hemostatic-net-use-in-facelift-surgery/Medxy AIvi2026-07-21T14:48:33-07:00Bên dưới bề mặt: Xác định độ sâu động mạch cảnh để sử dụng lưới cầm máu an toàn trong phẫu thuật căng da mặt https://news.medxy.ai/what-lies-beneath-navigating-carotid-artery-depth-for-safe-hemostatic-net-use-in-facelift-surgery/Medxy AIen2026-07-21T14:47:46-07:00What Lies Beneath: Navigating Carotid Artery Depth for Safe Hemostatic Net Use in Facelift Surgery https://news.medxy.ai/zh/dorsal-preservation-rhinoplasty-2/Medxy AIzh2026-07-21T12:05:56-07:00鼻背保留隆鼻术解析：逾千例病例带来的分类与实践启示 https://news.medxy.ai/ja/dorsal-preservation-rhinoplasty/Medxy AIja2026-07-21T12:05:37-07:001,191例から読み解く鼻背温存鼻形成術：発展、分類、そして最適化の要点 https://news.medxy.ai/vi/dorsal-preservation-rhinoplasty-insights-and-classification-from-over-a-thousand-cases/Medxy AIvi2026-07-21T12:05:17-07:00Làm rõ về phẫu thuật nâng mũi bảo tồn sống mũi: Những hiểu biết và phân loại từ hơn một nghìn ca lâm sàng https://news.medxy.ai/clarifying-dorsal-preservation-rhinoplasty-insights-and-classification-from-over-a-thousand-cases/Medxy AIen2026-07-21T12:04:21-07:00Clarifying Dorsal Preservation Rhinoplasty: Insights and Classification from Over a Thousand Cases https://news.medxy.ai/zh/2-year-psychiatric-and-neurologic-risks-after-infections/Medxy AIzh2026-07-21T10:43:03-07:00因感染住院后2年内精神与神经系统风险的图谱 https://news.medxy.ai/ja/2-year-psychiatric-and-neurologic-risks-after-infections-across-body-systems-and-age-groups/Medxy AIja2026-07-21T10:42:40-07:00感染症後2年間の精神・神経学的リスクを身体系・年齢層別に可視化する：統合的レビュー https://news.medxy.ai/vi/mapping-2-year-psychiatric-and-neurologic-risks-after-infections-across-body-systems-and-age-groups/Medxy AIvi2026-07-21T10:42:16-07:00Lập bản đồ nguy cơ tâm thần và thần kinh trong 2 năm sau nhiễm trùng theo hệ cơ quan và nhóm tuổi: Tổng quan tích hợp https://news.medxy.ai/mapping-2-year-psychiatric-and-neurologic-risks-after-infections-across-body-systems-and-age-groups-an-integrative-review/Medxy AIen2026-07-21T10:41:00-07:00Mapping 2-Year Psychiatric and Neurologic Risks After Infections Across Body Systems and Age Groups: An Integrative Review https://news.medxy.ai/zh/tissue-hypoperfusion-with-vasopressor-in-refractory-septic-shock/Medxy AIzh2026-07-21T10:40:38-07:00联合组织低灌注标志物与血管活性药物剂量，可提升难治性脓毒性休克死亡风险分层 https://news.medxy.ai/ja/tissue-hypoperfusion-markers-with-vasopressor-dose-in-refractory-septic-shock/Medxy AIja2026-07-21T10:40:17-07:00組織低灌流マーカーと昇圧薬投与量の併用で、難治性敗血症性ショックの死亡リスク層別化が向上 https://news.medxy.ai/vi/tissue-hypoperfusion-markers-with-vasopressor-dose-enhances-mortality-risk-stratification-in-refractory-septic-shock/Medxy AIvi2026-07-21T10:39:49-07:00Kết hợp dấu ấn giảm tưới máu mô với liều thuốc vận mạch giúp tăng độ chính xác phân tầng nguy cơ tử vong trong sốc nhiễm khuẩn kháng trị https://news.medxy.ai/combining-tissue-hypoperfusion-markers-with-vasopressor-dose-enhances-mortality-risk-stratification-in-refractory-septic-shock/Medxy AIen2026-07-21T10:38:50-07:00Combining Tissue Hypoperfusion Markers with Vasopressor Dose Enhances Mortality Risk Stratification in Refractory Septic Shock https://news.medxy.ai/zh/decannulation-success-in-neurologic-patients-with-abdominal-electrical-stimulation/Medxy AIzh2026-07-21T10:38:10-07:00腹部电刺激助力神经系统疾病患者成功拔管：联合气道廓清技术的临床价值 https://news.medxy.ai/ja/decannulation-success-in-neurologic-patients-the-role-of-abdominal-electrical-stimulation/Medxy AIja2026-07-21T10:37:53-07:00神経疾患患者における気管カニューレ抜去の成功率向上：気道クリアランス手技と腹部電気刺激の併用による役割 https://news.medxy.ai/vi/enhancing-decannulation-success-in-neurologic-patients-the-role-of-abdominal-electrical-stimulation/Medxy AIvi2026-07-21T10:37:34-07:00Tăng tỷ lệ rút canuyn thành công ở bệnh nhân thần kinh: Vai trò của kích thích điện bụng kết hợp kỹ thuật làm sạch đường thở https://news.medxy.ai/enhancing-decannulation-success-in-neurologic-patients-the-role-of-abdominal-electrical-stimulation-combined-with-airway-clearance-techniques/Medxy AIen2026-07-21T10:36:43-07:00Enhancing Decannulation Success in Neurologic Patients: The Role of Abdominal Electrical Stimulation Combined With Airway Clearance Techniques https://news.medxy.ai/zh/awake-intubation-in-emergency/Medxy AIzh2026-07-21T10:33:03-07:00急诊清醒插管的十年回顾：发生率、技术与结局 https://news.medxy.ai/ja/awake-intubation-in-emergency-settings/Medxy AIja2026-07-21T10:32:49-07:00救急現場における覚醒下挿管：気道レジストリ10年解析からみた発生頻度・手技・転帰 https://news.medxy.ai/vi/awake-intubation-in-emergency-settings-incidence-techniques-and-outcomes/Medxy AIvi2026-07-21T10:32:04-07:00Đặt nội khí quản khi bệnh nhân còn tỉnh trong cấp cứu: Tần suất, kỹ thuật và kết cục từ dữ liệu đăng ký đường thở trong 10 năm https://news.medxy.ai/awake-intubation-in-emergency-settings-incidence-techniques-and-outcomes-from-a-decade-of-airway-registries/Medxy AIen2026-07-21T10:31:16-07:00Awake Intubation in Emergency Settings: Incidence, Techniques, and Outcomes from a Decade of Airway Registries https://news.medxy.ai/zh/opioid-use-disorder-and-overdose-risk-in-older-adults/Medxy AIzh2026-07-21T10:08:09-07:00老年人阿片类药物使用障碍与过量风险预测：预后模型评估 https://news.medxy.ai/ja/opioid-use-disorder-and-overdose-risk-in-older-adults-evaluating-prognostic-models/Medxy AIja2026-07-21T10:07:52-07:00高齢者のオピオイド使用障害と過量投与リスクを予測する：予後予測モデルの評価 https://news.medxy.ai/vi/predicting-opioid-use-disorder-and-overdose-risk-in-older-adults/Medxy AIvi2026-07-21T10:07:31-07:00Dự đoán nguy cơ rối loạn sử dụng opioid và quá liều ở người cao tuổi: Đánh giá các mô hình tiên lượng https://news.medxy.ai/predicting-opioid-use-disorder-and-overdose-risk-in-older-adults-evaluating-prognostic-models/Medxy AIen2026-07-21T10:06:40-07:00Predicting Opioid Use Disorder and Overdose Risk in Older Adults: Evaluating Prognostic Models https://news.medxy.ai/zh/physicians-clinical-knowledge-and-reduction-of-low-value-services/Medxy AIzh2026-07-21T07:42:51-07:00医师临床知识与老年人低价值医疗服务减少的相关性 https://news.medxy.ai/ja/physicians-clinical-knowledge-in-older-adults/Medxy AIja2026-07-21T07:42:27-07:00一般内科医の臨床知識は高齢者への低価値医療の抑制と関連 https://news.medxy.ai/vi/physicians-clinical-knowledge-and-reduction-of-low-value-services-in-older-adults/Medxy AIvi2026-07-21T07:42:02-07:00Kiến thức lâm sàng của bác sĩ liên quan thế nào đến việc giảm dịch vụ y tế kém giá trị ở người cao tuổi? https://news.medxy.ai/correlation-between-physicians-clinical-knowledge-and-reduction-of-low-value-services-in-older-adults/Medxy AIen2026-07-21T07:40:24-07:00Correlation Between Physicians’ Clinical Knowledge and Reduction of Low-Value Services in Older Adults https://news.medxy.ai/ja/acp-calls-of-us-dietary-supplement-rules/Medxy AIja2026-07-21T07:35:15-07:00ACP、米国の栄養補助食品規制の抜本見直しを提言―2026年声明論文の重要ポイント https://news.medxy.ai/vi/acp-calls-of-u-s-dietary-supplement-rules/Medxy AIvi2026-07-21T07:34:30-07:00ACP kêu gọi cải tổ toàn diện quy định về thực phẩm bổ sung tại Hoa Kỳ: Những khuyến nghị then chốt từ quan điểm năm 2026 https://news.medxy.ai/zh/acp-calls-for-overhaul-of-u-s-dietary-supplement-rules/Medxy AIzh2026-07-21T07:33:48-07:00ACP呼吁全面改革美国膳食补充剂监管：2026年立场文件的核心建议 https://news.medxy.ai/acp-calls-for-overhaul-of-u-s-dietary-supplement-rules-key-recommendations-from-the-2026-position-paper/Medxy AIen2026-07-21T07:31:01-07:00ACP Calls for Overhaul of U.S. Dietary Supplement Rules: Key Recommendations from the 2026 Position Paper https://news.medxy.ai/zh/mrd-as-a-prognostic-biomarker-in-azacitidine-and-venetoclax-treated-aml/Medxy AIzh2026-07-20T23:30:06-07:00法国 VENAURA 登记库揭示：一线阿扎胞苷联合维奈克拉治疗 AML 中，MRD 可作为强预后生物标志物 https://news.medxy.ai/ja/mrd-as-a-prognostic-biomarker-in-frontline-azacitidine-and-venetoclax-treated-aml/Medxy AIja2026-07-20T23:29:44-07:00フランスVENAURAレジストリが示す、アザシチジン＋ベネトクラクス治療AMLにおけるMRDの予後的意義 https://news.medxy.ai/vi/measurable-residual-disease-as-a-prognostic-biomarker-in-frontline-azacitidine-and-venetoclax-treated-aml/Medxy AIvi2026-07-20T23:29:19-07:00Bệnh tồn dư tối thiểu có thể đo được: dấu ấn tiên lượng nổi bật ở AML điều trị azacitidine và venetoclax hàng đầu – Góc nhìn từ cơ sở đăng ký VENAURA của Pháp https://news.medxy.ai/measurable-residual-disease-as-a-prognostic-biomarker-in-frontline-azacitidine-and-venetoclax-treated-aml-insights-from-the-french-venaura-registry/Medxy AIen2026-07-20T23:27:51-07:00Measurable Residual Disease as a Prognostic Biomarker in Frontline Azacitidine and Venetoclax-Treated AML: Insights from the French VENAURA Registry https://news.medxy.ai/zh/blinatumomab-in-high-risk-ph-negative-b-cell-all/Medxy AIzh2026-07-20T23:27:02-07:00Blinatumomab 用于高危 Ph 阴性 B-ALL 巩固治疗：GRAALL-2014/B-QUEST 研究结果 https://news.medxy.ai/ja/blinatumomab-consolidation-in-high-risk-ph-negative-b-cell-all/Medxy AIja2026-07-20T23:26:25-07:00高リスクPh陰性B細胞性急性リンパ芽球性白血病に対するブリナツモマブ地固め療法：GRAALL-2014/B-QUEST試験からの知見 https://news.medxy.ai/vi/blinatumomab-consolidation-in-high-risk-ph-negative-b-cell-acute-lymphoblastic-leukemia/Medxy AIvi2026-07-20T23:25:58-07:00Blinatumomab trong giai đoạn củng cố cho B-ALL Ph- nguy cơ cao: Những phát hiện từ nghiên cứu GRAALL-2014/B-QUEST https://news.medxy.ai/blinatumomab-consolidation-in-high-risk-ph-negative-b-cell-acute-lymphoblastic-leukemia-insights-from-the-graall-2014-b-quest-study/Medxy AIen2026-07-20T23:24:43-07:00Blinatumomab Consolidation in High-Risk Ph-Negative B-Cell Acute Lymphoblastic Leukemia: Insights from the GRAALL-2014/B-QUEST Study https://news.medxy.ai/ja/effectiveness-of-adjuvanted-rsvpref3-vaccine-in-rsv-related-hospitalization-among-us-adults-aged-%e2%89%a560-years/Medxy AIja2026-07-20T22:29:40-07:00高齢者のRSV関連入院を防ぐRSVPreF3ワクチンの実臨床有効性：米国60歳以上を対象とした包括的レビュー https://news.medxy.ai/vi/effectiveness-of-adjuvanted-rsvpref3-vaccine-in-preventing-rsv-related-hospitalization-among-us-adults-aged-%e2%89%a560-years/Medxy AIvi2026-07-20T22:29:05-07:00Hiệu quả thực tế của vắc xin RSVPreF3 có bổ trợ trong phòng ngừa nhập viện do RSV ở người lớn từ 60 tuổi trở lên tại Hoa Kỳ: Tổng quan toàn diện https://news.medxy.ai/real-world-effectiveness-of-adjuvanted-rsvpref3-vaccine-in-preventing-rsv-related-hospitalization-among-us-adults-aged-%e2%89%a560-years-a-comprehensive-review/Medxy AIen2026-07-20T22:25:57-07:00Real-world Effectiveness of Adjuvanted RSVPreF3 Vaccine in Preventing RSV-Related Hospitalization Among US Adults Aged ≥60 Years: A Comprehensive Review